Zacks Research Has Optimistic View of APLS FY2025 Earnings

Key Points

• Zacks Research has increased its FY2025 earnings estimate for Apellis Pharmaceuticals to ($1.81) per share, slightly better than the previous forecast of ($1.82).
• Multiple research firms have raised their target prices for Apellis, with Citigroup increasing its target from $41.00 to $46.00 and maintaining a "buy" rating.
• Despite positive earnings revisions, Apellis Pharmaceuticals' stock is down 2.9%, currently trading at $23.13 with a market capitalization of $2.92 billion.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at Zacks Research upped their FY2025 earnings estimates for shares of Apellis Pharmaceuticals in a research report issued on Tuesday, September 16th. Zacks Research analyst Team now anticipates that the company will post earnings of ($1.81) per share for the year, up from their prior estimate of ($1.82). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals' Q4 2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.52) EPS, Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.36) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.11. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. The business had revenue of $171.39 million for the quarter, compared to the consensus estimate of $187.91 million. During the same period last year, the firm posted ($0.30) earnings per share. Apellis Pharmaceuticals's quarterly revenue was down 10.6% on a year-over-year basis.

Several other equities analysts have also recently issued reports on the company. Royal Bank Of Canada lifted their price objective on Apellis Pharmaceuticals from $17.00 to $19.00 and gave the stock a "sector perform" rating in a report on Friday, August 1st. Robert W. Baird upped their price objective on Apellis Pharmaceuticals from $47.00 to $50.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Bank of America raised their target price on shares of Apellis Pharmaceuticals from $23.00 to $24.00 and gave the company a "neutral" rating in a research note on Wednesday, July 16th. Wells Fargo & Company lifted their price target on shares of Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an "equal weight" rating in a research note on Monday, June 2nd. Finally, JPMorgan Chase & Co. increased their price target on shares of Apellis Pharmaceuticals from $35.00 to $37.00 and gave the stock an "overweight" rating in a report on Monday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $34.12.

Apellis Pharmaceuticals Stock Down 1.6%

Shares of APLS stock traded down $0.37 during trading hours on Thursday, reaching $23.01. 3,190,607 shares of the company's stock were exchanged, compared to its average volume of 1,971,140. The stock has a market cap of $2.91 billion, a PE ratio of -12.64 and a beta of 0.73. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $35.72. The stock's fifty day moving average price is $24.27 and its two-hundred day moving average price is $21.24. The company has a current ratio of 3.77, a quick ratio of 3.16 and a debt-to-equity ratio of 2.90.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in APLS. Assetmark Inc. grew its position in shares of Apellis Pharmaceuticals by 3,938.7% during the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company's stock worth $27,000 after buying an additional 1,221 shares during the period. Parallel Advisors LLC lifted its holdings in Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock valued at $33,000 after acquiring an additional 855 shares during the period. Osaic Holdings Inc. grew its holdings in Apellis Pharmaceuticals by 141.2% during the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company's stock valued at $47,000 after buying an additional 1,570 shares in the last quarter. GF Fund Management CO. LTD. raised its position in Apellis Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock valued at $70,000 after purchasing an additional 573 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Apellis Pharmaceuticals by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company's stock worth $84,000 after buying an additional 655 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Apellis Pharmaceuticals

In related news, CEO Cedric Francois sold 175,037 shares of the company's stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $28.19, for a total transaction of $4,934,293.03. Following the completion of the transaction, the chief executive officer owned 357,909 shares of the company's stock, valued at approximately $10,089,454.71. This represents a 32.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel David O. Watson sold 5,000 shares of Apellis Pharmaceuticals stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $24.34, for a total transaction of $121,700.00. Following the completion of the sale, the general counsel owned 118,730 shares in the company, valued at approximately $2,889,888.20. This represents a 4.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 430,919 shares of company stock valued at $10,656,945. 6.50% of the stock is currently owned by company insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).